Siltuximab monotherapy improves progression free survival compared to rituximab-based therapies in patients with idiopathic multicentric Castleman disease; indirect comparison of studies using single-arm metanalysis method and the generalized linear mixed model [PDF]
Annals of HematologySiltuximab is the only approved treatment for idiopathic multicentric Castleman Disease but in many countries the only available treatment is rituximab based.
Lazaros Karatisidis +9 more
doaj +2 more sources
Siltuximab for chimeric antigen receptor T-cell therapy–related CRS and ICANS: a multicenter retrospective analysis [PDF]
Blood Advances: Chimeric antigen receptor T-cell (CAR-T) therapies are effective in many hematologic malignancies; however, adverse events including cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS) can affect a ...
Amneet Bajwa +16 more
doaj +2 more sources
Siltuximab for the treatment of early complications after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia in children, adolescents, and young adults [PDF]
Experimental Hematology & OncologyBackground Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) are complications associated with CAR T-cell therapy. Siltuximab directly binds interleukin-6 (IL-6) and may be safe and effective as first-line
Víctor Galán-Gómez +20 more
doaj +2 more sources
Real-practice management and treatment of idiopathic multicentric Castleman disease with siltuximab: a collection of clinical experiences [PDF]
Drugs in ContextCastleman disease (CD) is a group of lymphoproliferative disorders that share common histopathological features yet have widely different aetiologies, clinical features and grades of severity as well as treatments and outcomes.
Bernardo Rossini +12 more
doaj +2 more sources
The value of a PET scan in selecting the best lymph node to biopsy, and confirming the diagnosis of idiopathic multicentric Castleman disease with HLH and EBV viremia in a previously healthy adult [PDF]
European Journal of Case Reports in Internal MedicineIntroduction: Castleman disease (CD) is a rare lymphoproliferative disorder having a variegated clinical presentation. Diagnosis of the idiopathic HIV- and HHV8-negative multicentric CD (iMCD) subtype poses a challenge given its non-specific clinical ...
Erica Bitektine +4 more
doaj +2 more sources
Successfully treated with siltuximab and prednisone in a 7-year-old girl with DOCK8-deficiency presenting as recurrent wart-like lesions: a case report [PDF]
Frontiers in ImmunologyDedicator of cytokinesis 8 (DOCK8) deficiency represents a primary immunodeficiency with a wide range of clinical symptoms, including recurrent infections, atopy, and increased malignancy risk.
Zhe Sun +45 more
doaj +2 more sources
Diagnostic challenges in patients with Castleman disease, a single center experience from Hungary [PDF]
Pathology and Oncology ResearchCastleman disease is a rare and atypical lymphoproliferative disorder characterized by diverse clinical manifestations. It has both unicentric and multicentric forms, the latter with further subdivisions, i.e., human herpesvirus 8-associated and ...
Boglárka Brúgós +6 more
doaj +2 more sources
Siltuximab in Idiopathic Multicentric Castleman Disease: Real-World Experience. [PDF]
J HematolCastleman disease (CD) is a very rare, non-malignant lymphoproliferative disorder that can be classified as unicentric or multicentric (MCD). MCD is associated with systemic symptoms, including organ dysfunction due to cytokine dysregulation, primarily interleukin-6 (IL-6).
Jitaru C +26 more
europepmc +3 more sources
Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial [PDF]
Trials, 2020 Objectives The purpose of this study is to test the safety and effectiveness of individually or simultaneously blocking IL-6, IL-6 receptor and IL-1 versus standard of care on blood oxygenation and systemic cytokine release syndrome in patients with ...
Bastiaan Maes +16 more
doaj +3 more sources
Novel use of Siltuximab in a patient with VEXAS Syndrome. [PDF]
Ann HematolVEXAS syndrome (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) is an increasingly recognized disorder that occurs due to somatic mutations of a ubiquitin-activating enzyme encoded by ubiquitin-like modifier activating enzyme 1 gene, UBA1. Clinical findings associated with VEXAS syndrome include recurrent fevers, polychondritis, periorbital ...
Cáceres-Nazario B +4 more
europepmc +3 more sources